Tiludronate: Bone pharmacology and safety
- 1 November 1995
- Vol. 17 (5) , S473-S477
- https://doi.org/10.1016/8756-3282(95)00344-9
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Effects of tiludronate on bone loss in paraplegic patientsJournal of Bone and Mineral Research, 1995
- Effects of tiludronate on bone mass, structure, and turnover at the epiphyseal, primary, and secondary spongiosa in the proximal tibia of growing rats after sciatic neurectomyJournal of Bone and Mineral Research, 1994
- Effects of the bisphosphonate tiludronate on bone resorption, calcium balance, and bone mineral densityJournal of Bone and Mineral Research, 1993
- Phosphate homeostasis, 1,25-dihydroxyvitamm D3, and hyperparathyroidism in early chronic renal failureTrends in Endocrinology & Metabolism, 1992
- Longitudinal effect of tiludronate on bone mineral density, resonant frequency, and strength in monkeysJournal of Bone and Mineral Research, 1992
- Efficacy and safety of the bisphosphonate tiludronate for the treatment of tumor-associated hypercalcemiaBone and Mineral, 1991
- Inflammation-mediated osteopenia (IMO): No change in bone resorption during its developmentCalcified Tissue International, 1991
- Inflammation-mediated osteopenia (IMO) during acute inflammation in rats is due to a transient inhibition of bone formationCalcified Tissue International, 1987
- Inflammation-Mediated Osteopenia in the Rat: A New Animal Model for Pathological Loss of Bone Mass*Endocrinology, 1984
- Prevention by a Diphosphonate of Immobilization “Osteoporosis” in RatsNature, 1969